Redsiway is ineffective in reducing the death rate of the new crown.

The WHO today released some information from the largest new coronary Phase III clinical Solidarity trial to date, with the exception of the old drug symethon, and three other therapies (Redsivir, hydroxychloroquine, Lopinavir/interferon combinations) that did not show a reduction in mortality and intestor risk in patients with new crowns.
the trial recruited a total of 11,266 new patients who needed to be hospitalized, and the Redsiway group had 2,750 people who shared the drug for 10 days.
not only did not reduce mortality, but the trial also found that the drug reduced hospital stay, but that was not the main endpoint of the trial.
drug source analysis This trial uses a total of four old drugs, hoping to find some new drugs tailored for the new crown before the emergence of some of the urgent old drug transition.
and interferon were used in SARS emergency treatment more than a decade ago, but were not supported by controlled trial data.
surprisingly reduced mortality by 20 percent, but mainly benefited patients with severe illnesses, who appeared to be more at risk from medication, a message not known before the controlled trial.
interferon alpha showed some efficacy in a small SARS trial, and a small phase II clinical trial in Hong Kong in the new crown seemed to signal a bit, but this trial showed that the interferon preparation was ineffective in reducing mortality.
a small company in the UK made an inhaler of interferon beta, and the phase II clinically announced previously appeared to have some effect.
the drug is clinically in the process.
hydroxychloroquine for years as a broad-spectrum antiviral drug, but there has been no chance of a real viral infection.
developed as an Ebola drug and has some in-body activity in other coronaviruses.
the new crown, the cellular system used in the Wuhan virus sifted through seven known drugs, both of which were the most active at 1uM level.
a controversial French virologist used hydroxychloroquine to conduct a leaky experiment that claimed to be working well, causing global attention.
hydroxychloroquine has now been done in multiple phase III clinical, almost certainly no therapeutic effect.
redsiwe because of direct interference with virus replication, so the system is more reliable, but also the greatest hope, once translated into the people's hope.
but the Redsivir Phase III clinic, led by Chinese scientists, showed no effect, especially since the absence of a reduction in viral load made it highly doubtful what the drug's level was.
later ACTT-1 trials led by the NIAID in the United States showed that Redsyvir could shorten hospital stays, but did not significantly reduce mortality or viral load.
looking back now, new coronary antibodies with lower respiratory exposure can reduce viral load, while Redsyvir as a small molecule antiviral drug does not show that the effect is unlikely to be very good.
redsiwe's most central problem is that it works for a while, and it doesn't work for a while.
playing erratic is a feature of poor technique and Messi never misses a game on a one-on-one.
's performance throughout the process was not flattering.
While the world was anxiously awaiting the exact efficacy of Redsiway, Gilead increased a non-controlled trial from 400 to 2,400 and later to 4,000, resulting in no valuable data.
later listed through the EUA channel with ACTT-1 results and is now priced at $2,340 for five days, on the grounds that a five-day hospital stay is also a gain.
is valuable for reducing hospital stays for patients, reducing the risk of cross-infection, and relieving stress in the health care system, but only if the benefits are real and reliable."
today's trial shows that the yield may not be reliable, and we don't need to guess here whether it is reliable.
method is very simple, the original 4000 people randomly singled out half of the do not give drugs to know how effective.
ineffective drugs are not only a pointless drain on social resources, but if used in large quantities, they can also have rare side effects on patients, with two reported cases last week of acute liver damage using Redsyvir.
not necessarily related to the drug, patients who do not have certain benefits should not be forced to take this risk.
.